Ginkgo Bioworks announced on April 10, 2025, a new contract with the Advanced Research Projects Agency for Health (ARPA-H), alongside partners Tritica Biosciences, US Pharmacopeia, On Demand Pharmaceuticals, and Isolere Bio by Donaldson. The contract is valued at $29 million.
This two-year program, named Wheat-based High efficiency Enzyme and API Technology (WHEAT), aims to establish a new manufacturing process for the distributed production of biologic and small molecule active pharmaceutical ingredients (APIs) using wheat germ cell-free expression systems. This strategy seeks to reshore and stabilize critical pharmaceutical supply chains.
Ginkgo Bioworks will apply its Enzyme Services and expertise in cell-free systems, leveraging machine learning and computational tools to engineer enzymes and optimize expression systems. The project focuses on developing affordable cell-free biological processes to produce essential medicines, including potential for growth factors and insulin.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.